Gut Microbe Veillonella Emerges as a Potential Driver of Pancreatic Cancer Progression

Pancreatic ductal adenocarcinoma remains one of the most lethal malignancies in modern medicine, with five-year survival rates that have barely improved despite decades of therapeutic advances. While genetic mutations such as KRAS activation and TP53 loss have long dominated the research agenda, a growing body of evidence points to a less obvious accomplice: the trillions of microorganisms inhabiting the human gut. A new study published in BMC Cancer now adds a compelling piece to this puzzle, identifying a common anaerobic bacterium, Veillonella, as a microbial taxon significantly enriched in the intestines of patients with advanced pancreatic cancer and providing multiple lines of evidence that it may actively promote the malignant behavior of pancreatic tumor cells.

The research, led by Jiangchuan Zhu, Yiwen Qiu, and colleagues at Longhua Hospital Shanghai University of Traditional Chinese Medicine, together with collaborators in Nanjing and Hefei, took an unusually comprehensive approach. Rather than relying on a single experimental technique, the team integrated three complementary methodologies: metagenomic sequencing of patient stool samples to identify differential bacterial taxa, direct bacteria-cell co-culture experiments to test functional effects on pancreatic cancer cell lines, and two-sample Mendelian randomization analysis using large-scale genome-wide association study data to probe potential genetic associations between Veillonella abundance and pancreatic cancer risk. This triangulation of observational, functional, and genetic evidence is what distinguishes the work from many earlier microbiome-cancer association studies that stopped at correlation.

The investigation began with metagenomic sequencing, a technique that sequences all genetic material in a sample rather than targeting specific known organisms, allowing researchers to profile the entire microbial community without cultivation bias. Comparing the intestinal microbiota of patients with advanced pancreatic cancer against healthy adult volunteers, the team found that the abundance of Veillonella, a genus of Gram-negative anaerobic cocci that is a normal inhabitant of the oral cavity and gut, was significantly increased in the cancer patients. Non-metric multidimensional scaling and other community-level analyses confirmed that the overall microbial landscape differed measurably between the two groups, with Veillonella standing out as one of the most notable differential taxa.

To determine whether this enrichment was merely a byproduct of the disease environment or something with biological consequence, the researchers selected representative bacterial taxa for direct co-culture experiments with two well-characterized pancreatic cancer cell lines, PANC-1 and BxPC-3. Using a multiplicity-of-infection-controlled co-incubation protocol, they exposed the cancer cells to live Veillonella parvula and then measured a battery of malignant phenotypes. Cell viability was assessed with the CCK-8 colorimetric assay, long-term proliferative capacity with colony formation assays, and motility with both wound healing scratch assays and Transwell migration chambers. The results were consistent across these readouts: Veillonella parvula significantly enhanced both the proliferation and the migration of pancreatic cancer cells in vitro, suggesting the bacterium is not a passive passenger but a potential active participant in tumor progression.

Seeking the molecular underpinnings of these phenotypic changes, the team performed transcriptomic sequencing on the co-cultured cancer cells and compared their gene expression profiles with those of untreated controls. The analysis identified a substantial set of differentially expressed genes, and pathway enrichment analysis using Gene Ontology and Kyoto Encyclopedia of Genes and Genomes frameworks revealed significant enrichment of genes belonging to the PI3K/AKT signaling pathway. This pathway, which transmits signals from growth factor receptors to promote cell survival, proliferation, and motility, is one of the most frequently dysregulated cascades in pancreatic ductal adenocarcinoma. Its transcriptional activation following bacterial exposure points to a plausible mechanistic route by which Veillonella could push cancer cells toward more aggressive behavior, although the authors are careful to note that this enrichment indicates a regulatory link that warrants further functional dissection rather than a fully proven causal mechanism.

Perhaps the most novel component of the study is its use of Mendelian randomization, a statistical technique that exploits naturally occurring genetic variation as a form of randomization to test whether an exposure is plausibly causally related to an outcome. Because genetic variants are fixed at conception, they are largely immune to the reverse causation and confounding that plague conventional observational studies. The researchers drew on summary statistics from large-scale genome-wide association studies, including data from the Dutch Microbiome Project linking genetic variants to gut microbiome composition, and from GWAS of pancreatic cancer risk. Using inverse variance weighted analysis as the primary method, supplemented by sensitivity analyses including MR-PRESSO to detect and correct for pleiotropic outliers, they found genetic evidence supporting a potential association between genetically predicted Veillonella abundance and pancreatic cancer risk, with an odds ratio of 1.39 and a 95 percent confidence interval of 1.05 to 1.83, corresponding to a P value of 0.02.

The authors are appropriately candid about the limitations of this genetic analysis. In their conclusion, they acknowledge that residual pleiotropy, the phenomenon in which genetic variants influence the outcome through pathways unrelated to the exposure, and weak instrument bias cannot be fully excluded. These caveats matter, because Mendelian randomization results in the microbiome field have sometimes failed to replicate, and an odds ratio near the boundary of statistical significance should be interpreted as suggestive rather than definitive. Nevertheless, the convergence of three independent lines of evidence, patient metagenomics, in vitro functional assays, and population-scale genetic association, makes a stronger cumulative case than any single method could provide on its own.

The findings also fit into a broader and rapidly evolving literature on the microbiome in pancreatic cancer. Previous work has documented intratumoral bacteria within pancreatic ductal adenocarcinoma specimens, shown that microbial translocation from the gut can influence the tumor immune microenvironment, and demonstrated in mouse models that antibiotic depletion of the microbiome can alter tumor growth and chemotherapy response. Lipopolysaccharide, a structural component of Gram-negative bacterial outer membranes that the study authors reference, is known to activate Toll-like receptor 4 signaling, which can intersect with inflammatory cascades and, in some contexts, potentiate oncogenic pathways. Veillonella’s metabolic profile, including its ability to consume lactate and convert it into short-chain fatty acids, offers additional plausible routes by which it could reshape the metabolic environment of the gut and, potentially, of the tumor itself.

From a clinical standpoint, the study raises the tantalizing but still distant prospect of microbiome-targeted interventions in pancreatic cancer. If Veillonella enrichment does contribute to disease progression in patients, then monitoring its abundance could conceivably serve as a biomarker, and modulating it through diet, probiotics, antibiotics, or fecal microbiota strategies could become part of a prevention or treatment toolkit. However, the authors and the field at large caution that in vitro co-culture findings do not automatically translate to the complex in vivo tumor microenvironment, and that the direction of causality in human patients remains difficult to establish with certainty. It is entirely possible that advanced pancreatic cancer alters gut ecology in ways that favor Veillonella, rather than the reverse, even in light of the genetic evidence.

What the study undeniably delivers is a rigorous, multi-pronged template for interrogating microbiome-cancer relationships, and a specific, testable hypothesis about a bacterial genus that most people carry harmlessly but which may behave differently in the context of pancreatic malignancy. The work, funded by the National Natural Science Foundation of China and conducted under ethical approval from Longhua Hospital with written informed consent from all participants, was published open access on 1 October 2026. As the authors state, their study provides, for the first time, genetic evidence supporting a potential causal link between Veillonella and pancreatic cancer, while acknowledging the inherent uncertainties of the method. The next steps will likely involve animal models, mechanistic dissection of the PI3K/AKT connection, and replication in independent patient cohorts, all of which will determine whether this common gut resident becomes a genuine therapeutic target or remains an intriguing correlation in one of medicine’s most stubborn diseases.

Subject of Research: The role of the gut bacterium Veillonella in pancreatic cancer progression

Article Title: Veillonella promotes pancreatic cancer progression as revealed by integrated functional, Mendelian randomization, and transcriptomic analyses

Article References: Zhu, J., Qiu, Y., Ren, M., Sun, X., Zhao, R., Ma, F., & Cao, N. (2026). Veillonella promotes pancreatic cancer progression as revealed by integrated functional, Mendelian randomization, and transcriptomic analyses. BMC Cancer. https://doi.org/10.1186/s12885-026-17050-7

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17050-7

Keywords: pancreatic cancer, Veillonella, gut microbiota, metagenomics, Mendelian randomization, PI3K/AKT signaling, tumor microbiome, Veillonella parvula, cell proliferation, cancer migration, GWAS, BMC Cancer